HCV - AVI BioPharma Reports Narrower Q4 Loss, On 390% Higher Revenues ...

AVI BioPharma Reports Narrower Q4 Loss, On 390% Higher Revenues ...
Trading Markets, CA - Mar 8, 2006... In our clinical trial to treat the hepatitis C virus/HCV, we expect to report preliminary results from the second phase treating chronically infected HCV ...

FDA Sends Intermune Letter Over Advertisement
PharmaLive.com (press release), PA - Apr 4, 2006... INFERGEN is indicated for the treatment of chronic HCV infection in patients 18years of age or older with compensated liver disease who have anti-HCV serum ...

SP rises on deal and analyst upgrades
Pharma Times (subscription), UK - Mar 21, 2006... has signed an exclusive collaboration and licensing agreement for the development of PTC Therapeutic's preclinical hepatitis C virus (HCV) candidates, which ...

Human Genome tumbles on mixed drug data
MarketWatch - Mar 14, 2006... Albuferon is being tested in combination with the antiviral ribavirin to see if it can reduce levels of the hepatitis C virus, or HCV, in both patients who ...

Clinical Study Results of Actilon for Hepatitis C
EndoNurse, AZ - Mar 21, 2006... clinical study of Actilon (CPG 10101) in combinations with pegylated interferon and/or ribavirin for the treatment of chronic hepatitis C virus (HCV) in the ...